These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15855014)

  • 21. Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women.
    Fife KH; Wheeler CM; Koutsky LA; Barr E; Brown DR; Schiff MA; Kiviat NB; Jansen KU; Barber H; Smith JF; Tadesse A; Giacoletti K; Smith PR; Suhr G; Johnson DA
    Vaccine; 2004 Jul; 22(21-22):2943-52. PubMed ID: 15246631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody.
    Liu DW; Chang JL; Tsao YP; Huang CW; Kuo SW; Chen SL
    Int J Cancer; 2005 Jan; 113(1):93-100. PubMed ID: 15386434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
    Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
    Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.
    Davidson EJ; Boswell CM; Sehr P; Pawlita M; Tomlinson AE; McVey RJ; Dobson J; Roberts JS; Hickling J; Kitchener HC; Stern PL
    Cancer Res; 2003 Sep; 63(18):6032-41. PubMed ID: 14522932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles.
    Shebl FM; Pinto LA; García-Piñeres A; Lempicki R; Williams M; Harro C; Hildesheim A
    Cancer Epidemiol Biomarkers Prev; 2010 Apr; 19(4):978-81. PubMed ID: 20332253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
    Omori M; Pu R; Tanabe T; Hou W; Coleman JK; Arai M; Yamamoto JK
    Vaccine; 2004 Dec; 23(3):386-98. PubMed ID: 15530685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human Papillomavirus Vaccine-Induced Cytokine Messenger RNA Expression in Vaccinated Women.
    Gonçalves AK; Giraldo PC; Machado PR; Farias KJ; Costa AP; Freitas JC; Eleutério J; Witkin SS
    Viral Immunol; 2015; 28(6):339-42. PubMed ID: 25965646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
    Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
    J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
    Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ
    J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
    Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
    Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus vaccines.
    Stanley MA
    Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine.
    Olsson SE; Villa LL; Costa RL; Petta CA; Andrade RP; Malm C; Iversen OE; Høye J; Steinwall M; Riis-Johannessen G; Andersson-Ellstrom A; Elfgren K; von Krogh G; Lehtinen M; Paavonen J; Tamms GM; Giacoletti K; Lupinacci L; Esser MT; Vuocolo SC; Saah AJ; Barr E
    Vaccine; 2007 Jun; 25(26):4931-9. PubMed ID: 17499406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.
    Brown DR; Fife KH; Wheeler CM; Koutsky LA; Lupinacci LM; Railkar R; Suhr G; Barr E; Dicello A; Li W; Smith JF; Tadesse A; Jansen KU
    Vaccine; 2004 Jul; 22(21-22):2936-42. PubMed ID: 15246630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of human papilloma virus L1 virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activation.
    de Witte L; Zoughlami Y; Aengeneyndt B; David G; van Kooyk Y; Gissmann L; Geijtenbeek TB
    Immunobiology; 2007; 212(9-10):679-91. PubMed ID: 18086370
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes.
    Thönes N; Müller M
    Virology; 2007 Dec; 369(2):375-88. PubMed ID: 17822733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species.
    Gambhira R; Gravitt PE; Bossis I; Stern PL; Viscidi RP; Roden RB
    Cancer Res; 2006 Dec; 66(23):11120-4. PubMed ID: 17145854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-prime multi-boost strategy immunization with recombinant DNA, adenovirus, and MVA vector vaccines expressing HPV16 L1 induces potent, sustained, and specific immune response in mice.
    Li LL; Wang HR; Zhou ZY; Luo J; Xiao XQ; Wang XL; Li JT; Zhou YB; Zeng Y
    Antiviral Res; 2016 Apr; 128():20-7. PubMed ID: 26821205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites.
    Carter JJ; Madeleine MM; Shera K; Schwartz SM; Cushing-Haugen KL; Wipf GC; Porter P; Daling JR; McDougall JK; Galloway DA
    Cancer Res; 2001 Mar; 61(5):1934-40. PubMed ID: 11280749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
    Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
    Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.